Cleveland Clinic Researchers Explore Epigenetic Combo as Immunotherapy Booster
May 16th 2017
An epigenetic strategy under study at Cleveland Clinic combines THU, a cytidine deaminase inhibitor, with decitabine and nivolumab (Opdivo) in patients with non-small cell lung cancer. The results of early studies demonstrate that THU may help prime the immune system.